Skip Navigation

European Journal of Heart Failure 2005 7(5):859-864; doi:10.1016/j.ejheart.2005.01.017
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Varela-Roman, A.
Right arrow Articles by Gonzalez-Juanatey, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varela-Roman, A.
Right arrow Articles by Gonzalez-Juanatey, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society of Cardiology

Influence of diabetes on the survival of patients hospitalized with heart failure: A 12-year study

Alfonso Varela-Roman, Lilian Grigorian Shamagian, Eduardo Barge Caballero, Pilar Mazon Ramos, Pedro Rigueiro Veloso and Jose Ramon Gonzalez-Juanatey*

Santiago de Compostela Spain

* Corresponding author. Present address: Servicio de Cardiologia, Hospital Clinico de Santiago de Compostela, Spain. Tel.: +34 981 950 757; fax: +34 981 950 754. E-mial address: jose.ramon.gonzalez.juanatey{at}sergas.es


  Abstract

Aim: To investigate the influence of diabetes mellitus (DM) on the prognosis of heart failure (HF) patients, focussing specifically on aetiology and patients with preserved left ventricular systolic function (LVSF), which to date has not been fully investigated.

Method and results: 1659 Patients hospitalized for HF between 1991 and 2002 in the Cardiology Department of a tertiary hospital, aged 69±12years, 60% male were studied prospectively. Arterial hypertension was present in 54% of patients, DM in 26% and ischaemic cardiomyopathy in 51%. A survival analysis performed in April 2003 showed that DM worsens the prognosis of the whole group (median survival (MS):3.6 vs. 5.4 years; p<0.001), of ischaemic and non-ischaemic patients (MS: 3.8 vs. 4.9 years; p=0.13 and 3.6 vs. 6.0 years; p<0.001, respectively). A similar effect of DM was shown in patients with preserved LVSF (MS: 3.8 vs. 5.8 years; p=0.03) and in patients with impaired LVSF (3.6 vs. 6.3 years; p<0.0001).

Conclusion: DM increases mortality among HF patients with preserved and impaired LVSF and those without ischaemic cardiomyopathy.

Key Words: Heart failure • Diabetes mellitus • Prognosis

Received July 1, 2004; Revised October 27, 2004; Accepted January 27, 2005


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. Matsushima, S. Kinugawa, T. Yokota, N. Inoue, Y. Ohta, S. Hamaguchi, and H. Tsutsui
Increased myocardial NAD(P)H oxidase-derived superoxide causes the exacerbation of postinfarct heart failure in type 2 diabetes
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H409 - H416.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
C Tribouilloy, D Rusinaru, H Mahjoub, J-M Tartiere, L Kesri-Tartiere, S Godard, and M Peltier
Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study
Heart, November 1, 2008; 94(11): 1450 - 1455.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
H. Tominaga, H. Katoh, K. Odagiri, Y. Takeuchi, H. Kawashima, M. Saotome, T. Urushida, H. Satoh, and H. Hayashi
Different effects of palmitoyl-L-carnitine and palmitoyl-CoA on mitochondrial function in rat ventricular myocytes
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H105 - H112.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
E. Erdmann and R. G. Wilcox
Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure
Eur. Heart J., January 1, 2008; 29(1): 12 - 20.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.